

# Global Invasive Ductal Carcinoma Therapeutics Market Forecast To Reach \$12.55 Billion By 2029 With 8.6% Annual Growth

*The Business Research Company's  
Invasive Ductal Carcinoma Therapeutics  
Global Market Report 2025 – Market Size,  
Trends, And Global Forecast 2025-2034*

LONDON, GREATER LONDON, UNITED  
KINGDOM, June 30, 2025

/EINPresswire.com/ -- How Big Is The  
Global [Invasive Ductal Carcinoma  
Therapeutics Market](#) Expected To Grow?

The Business  
Research Company

The Business Research Company

“Showcasing robust growth, the invasive ductal carcinoma therapeutics market has seen significant expansion in recent years. The market which stood at \$8.3 billion in 2024, is projected to grow to \$9.03 billion in 2025, reflecting a compound annual growth rate CAGR of 8.9%. Factors such as an increase in breast cancer incidence, the widespread adoption of combination therapies, a rise in obesity and an aging population, the amplified use of hormone receptor testing, and growing government support for cancer research have contributed to this historical period growth.”

Save 30% On All Global  
Market Reports With Code  
ONLINE30– Stay Informed  
On Tariff Changes,  
Macroeconomic Trends, And  
More.”

*The Business Research  
Company*

What Is Its Annual Growth Rate?

In the next few years, the [invasive ductal carcinoma therapeutics market size](#) is expected to continue its strong growth, achieving a size of \$12.55 billion by 2029 with a compound annual growth rate CAGR of 8.6%. The advancement is attributed to rising preferences for personalized treatment approaches, increasing demand for minimally invasive surgical options, an increase in approvals of biosimilar monoclonal antibodies, a growing clinical pipeline of antibody-drug conjugates, and a rising emphasis on value-based cancer care models. Key trends to watch include the development of immune checkpoint inhibitors, integration of imaging and therapy systems, the incorporation of digital health platforms in patient management, innovation in

microRNA modulators, and innovation in nanoparticle drug delivery.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24574&type=smp>

What Is Driving The Growth Of The Invasive Ductal Carcinoma Therapeutics Market?

One of the key growth drivers of the invasive ductal carcinoma therapeutics market is the upswing in breast cancer incidences. Breast cancer is characterized by cells in the breast growing beyond control, creating a malignant tumor that can invade surrounding tissues or metastasize to other parts of the body. An increase in lifestyle-related factors such as obesity and physical inactivity, widely recognized for elevating the risk of developing malignant tumors in breast tissue, correlate with the increased incidence of breast cancer. Invasive ductal carcinoma therapeutics play an instrumental role in breast cancer management, offering targeted and effective therapies to counter tumor growth and spread by using precision medicines, improving patient outcomes and quality of life.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report>

Which Leading Companies Are Driving The Growth Of The Invasive Ductal Carcinoma Therapeutics Market Share?

Companies like Pfizer Inc., F. Hoffmann-La Roche AG, Merck And Co. Inc., AbbVie Inc., Bayer AG, Novartis International AG, AstraZeneca plc, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim, Mylan N.V., Daiichi Sankyo, Astellas Pharma Inc., Eisai Co. Ltd., BeiGene Ltd, Dr. Reddy's Laboratories, Cipla Limited, Seagen Inc., Glenmark Pharmaceuticals, Olema Pharmaceuticals Inc. are making a significant impact in the invasive ductal carcinoma therapeutics market.

What Are The Key Trends Of The Invasive Ductal Carcinoma Therapeutics Market?

In terms of emerging trends, major operators in the invasive ductal carcinoma IDC therapeutics market are focusing on developing innovative therapies, such as antibody-drug conjugates, to improve targeted treatment efficacy and reduce side effects.

How Is The Global Invasive Ductal Carcinoma Therapeutics Market Segmented?

The market can be segmented as follows:

- 1 By Drug Type: Targeted Therapy, Hormone Therapy
- 2 By Type: Hormone Receptor, Human Epidermal Growth Factor Receptor 2 HER2+, Triple-Negative Breast
- 3 By End Use: Hospitals, Oncology Clinics, Others

Subsegments are:

- 1 By Targeted Therapy: Monoclonal Antibodies, Tyrosine Kinase Inhibitors, Poly ADP Ribose Polymerase PARP Inhibitors, Proteasome Inhibitors
- 2 By Hormone Therapy: Aromatase Inhibitors, Selective Estrogen Receptor Modulators, Estrogen Receptor Downregulators, Luteinizing Hormone-Releasing Hormone Agonists

What Are The Leading Region In The Invasive Ductal Carcinoma Therapeutics Market?

Geographically, North America was the largest region in the invasive ductal carcinoma therapeutics market in 2024. The regions analyzed in the invasive ductal carcinoma therapeutics market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:

Appendiceal Cancer Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/appendiceal-cancer-treatment-global-market-report>

Metastatic Breast Cancer Treatment Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/metastatic-breast-cancer-treatment-global-market-report>

Breast Cancer Drugs Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report>

[About The Business Research Company:](#)

Learn More About The Business Research Company. Having published over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has earned a reputation for offering comprehensive, data-rich research and insights. Equipped with 1,500,000 datasets, the company's strength lies in its in-depth secondary research and unique insights from industry leaders, providing you with the information necessary to stay ahead of the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>  
Americas +1 3156230293

Asia +44 2071930708  
Europe +44 2071930708  
Email us at [info@tbrc.info](mailto:info@tbrc.info)

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: [https://www.youtube.com/channel/UC24\\_fI0rV8cR5DxICpgmyFQ](https://www.youtube.com/channel/UC24_fI0rV8cR5DxICpgmyFQ)

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham  
The Business Research Company  
+44 20 7193 0708  
[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/826963039>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.